Dyne therapeutics logo png
WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ... WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended …
Dyne therapeutics logo png
Did you know?
WebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ...
WebDyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was raised on Jan 21, 2024 from a Post-IPO Equity round. Dyne Therapeutics … WebFeb 8, 2024 · Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its ...
WebMar 2, 2024 · (EDGAR Online via COMTEX) -- 0001818794false00018187942024-03-022024-03-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K... WebDyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company …
WebFeb 9, 2024 · Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne …
WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & … ctdot division of traffic engineeringWebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). ctdot ev chargingWebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … earth batteries telluric currentsWebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ... ctdot form 815WebMar 24, 2024 · Dyne Therapeutics Inc Registered Shs's market capitalization is $642.40 M by 56.34 M shares outstanding. Dyne Therapeutics Stock Snapshot. ... Logos Global … ct dot division of materials testingWebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … ctdot highway designWebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT … ctdot headquarters